匹罗卡品
老花眼
医学
青光眼
眼科
不利影响
验光服务
皮肤病科
麻醉
药理学
精神科
癫痫
标识
DOI:10.58347/tml.2025.1719b
摘要
The FDA has approved pilocarpine 0.4% preservative-free ophthalmic solution (Qlosi – Orasis) for treatment of presbyopia in adults. Pilocarpine 1.25% ophthalmic solution (Vuity) was approved in 2021 for the same indication.1 Pilocarpine 1%, 2%, and 4% ophthalmic solutions (Isopto Carpine, and others) have been available for years for treatment of glaucoma, but local (e.g., blurry vision and instillation-site pain) and systemic (e.g., sweating and GI disturbances) adverse effects have limited their use.
科研通智能强力驱动
Strongly Powered by AbleSci AI